Impact of post-Acute respiratory distress syndrome COVID sedation on late neuroinflammation (PET-DEXDOCOVID)

Korábbi kezelés

• Poor vaccine tolerance requiring hospitalisation
• Severe surgical traumatism such as cranial trauma or polytraumatism

Más betegség

• Serious neurological history on admission to the intensive care unit: o Cerebrovascular accident o Severe head trauma o Dementia with loss of autonomy
• New severe COVID infection of the ARDS type
• New severe bacterial infection of the severe sepsis type

Laborértékek

• Severe renal insufficiency (creatinine clearance < 30 mL/min)

Egyéb

• Protected adults (under court protection, guardianship or curatorship)
• Pregnant or breast-feeding
• Contraindication to a PET or MRI scan
• Contraindication to the administration of the radiopharmaceutical [18F]-DPA-714

• Patients over the age of majority (age ≥ 18 years at the time of inclusion) and under 75 years of age
  • COVID-19 infection documented by nasopharyngeal PCR test.
• TPSO genotyping homozygous high affinity for [18F]-DPA-714 or heterozygous intermediate affinity for [18F]-DPA-714.
• Patient admitted to intensive care for ARDS following COVID infection requiring mechanical ventilation and deep sedation for at least 24 hours.
• Patient alive 24 months (+24 months) after discharge from intensive care unit
• Signature of free and informed consent
• Patient affiliated to a social security scheme, excluding AME (state medical aid)
  • For the group of patients exposed to dexmedetomidine : - Administration of dexmedetomidine for at least 24 hours during hospitalisation in intensive care.
  • For the group of patients not exposed to dexmedetomidine : - No administration of dexmedetomidine during hospitalisation in the intensive care unit.